AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Keysight Receives Frost & Sullivan's 2025 Global Company of the Year Award for 6G Excellence.
ByAinvest
Friday, Aug 1, 2025 7:07 pm ET1min read
Canaccord raises Illumina's (ILMN) price target from $99 to $105 and maintains a Hold rating after the company's Q2 2025 results exceeded estimates and FactSet consensus. The updated target reflects anticipated revenue growth and a slight improvement in operating margins. Illumina's high-throughput technology is crucial for whole-genome sequencing, and its microarrays enable cost-effective genetic screening. The company's revenue over the past year is $4.337 billion, with a recent decline in revenue growth of -4.1% YoY.
Canaccord Genuity analyst Kyle Mikson maintained a Hold rating on Illumina (ILMN) stock while raising the price target from $99 to $105 following the company's Q2 2025 earnings report. The updated target reflects anticipated revenue growth and a slight improvement in operating margins [1].Illumina reported quarterly earnings of $1.19 per share, beating the analyst consensus estimate of $1.01 per share. The company also posted quarterly sales of $1.059 billion, exceeding the analyst consensus estimate of $1.049 billion. The earnings were driven by the continued ramp in X consumables and accelerating growth in the clinical segment, which is the company's largest customer segment [1].
The company's high-throughput technology is crucial for whole-genome sequencing, and its microarrays enable cost-effective genetic screening. Illumina's revenue over the past year was $4.337 billion, with a recent decline in revenue growth of -4.1% YoY [1].
The stock's post-earnings decline underscores investor skepticism, with ILMN trading 33% below its 52-week high of $156.66, despite a strong EPS beat of 17.8%. The market appears to be pricing in continued pressure from NIH funding uncertainty, competitive threats, and the gradual transition to the NovaSeq X platform [2].
Illumina's 2025 strategy is anchored in transformative technologies poised to redefine the industry, including Constellation Mapped Read Technology, Spatial Transcriptomics, 5-Base Methylation Analysis, and Multiomics Integration. These innovations are supported by strategic acquisitions and partnerships, positioning Illumina to benefit from the $10B+ growth in precision medicine [2].
References:
[1] https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/46800842/these-analysts-boost-their-forecasts-on-illumina-following-upbeat-results
[2] https://www.ainvest.com/news/illumina-earnings-dilemma-stock-sharp-decline-buying-opportunity-2508/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet